Mate Health launches at-home sperm DNA fragmentation test

Mate Health has launched a new at-home Sperm DNA Fragmentation Test for fertility and recurrent pregnancy loss evaluations through physician practices. The test is designed to surface sperm DNA damage that standard semen analysis does not measure, as ASRM’s updated guidance gives the test new clinical relevance.

Why it matters: - Sperm DNA fragmentation testing can identify sperm DNA damage that conventional semen analysis does not capture. - The test may help physicians evaluate otherwise unexplained recurrent miscarriage, recurrent pregnancy loss with infertility and select male fertility cases. - More accessible at-home testing could expand access for patients outside major metro areas and reduce logistics for physician practices.

What happened: - Mate Health launched its Sperm DNA Fragmentation Test for use in fertility and recurrent pregnancy loss evaluations through physician practices. - The company offers the test through at-home collection and a digital ordering workflow. - Mate Health also offers an Advanced Semen Analysis that combines Comprehensive Semen Analysis with DNA fragmentation and vitality testing. - More information is available at the company's announcement.

The details: - Sperm DNA fragmentation testing measures damage to the genetic material carried by sperm. - Standard semen analysis looks at concentration, motility and morphology, but not sperm DNA integrity. - Mate Health says the test is processed in a CLIA-certified, CAP-accredited high-complexity andrology laboratory. - Mate Health uses its validated Active Cooling transport system before laboratory processing. - Results are available within 24 hours of laboratory receipt. - Patient and physician reports are delivered through Mate Health’s secure reporting platform. - Physician reports are also available by fax. - Physicians can recommend the test as part of a fertility evaluation when appropriate. - Practices can offer testing without stocking kits or managing specimen logistics. - Mate Health’s testing lineup also includes Comprehensive Semen Analysis and Post-Vasectomy Semen Analysis.

Between the lines: - The launch aligns with updated 2026 guidance from the American Society for Reproductive Medicine on recurrent pregnancy loss. - ASRM says sperm DNA fragmentation testing may be considered in otherwise unexplained recurrent miscarriage or recurrent pregnancy loss with concomitant infertility. - ASRM also notes elevated sperm DNA fragmentation is associated with miscarriage, but more research is needed on whether treatment improves pregnancy outcomes. - A reproductive urologist on Mate Health’s Medical Advisory Board said DNA fragmentation testing is not a replacement for semen analysis and is not appropriate for every patient. - The new test gives clinicians another data point when standard semen analysis does not explain fertility problems.

What's next: - Physicians can begin incorporating the test into fertility and recurrent pregnancy loss workups when clinically appropriate. - Mate Health is likely to market the test alongside its other at-home male fertility offerings through physician practices. - The company’s model depends on continued clinician adoption of at-home workflows and broader use of DNA fragmentation testing in selected cases.

The bottom line: - Mate Health is betting that updated clinical guidance and easier at-home collection will make sperm DNA fragmentation testing a more routine next step in male fertility care.